Revvity | PKI - Current Liabilities


Revvity reported $701.48M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Agilent USD 2.29B 20M Jun/2026
Align Technology USD 1.91B 4.9M Sep/2026
Bio Techne USD 361.27M 197.57M Sep/2026
Bio-Rad Laboratories USD 969.1M 7.8M Sep/2026
Bruker USD 1.17B 32.6M Sep/2026
Celltrion KRW 288.01B 4.7B Jun/2026
Charles River Laboratories USD 1.09B 45.49M Sep/2026
Cspc Pharmaceutical CNY 10.18B 65.36M Dec/2025
Danaher USD 9.05B 945M Sep/2026
Dentsply International USD 1.22B 32M Sep/2026
Deva Holding AS TRY 6.43B 1.18B Sep/2023
Dianthus Therapeutics USD 28.51M 5.87M Sep/2026
Divis Laboratories Ltd INR 27.07B 6.64B Sep/2026
Edwards Lifesciences USD 1.58B 68.8M Sep/2026
Illumina USD 1.16B 422M Sep/2026
Intuitive Surgical USD 3.23B 652.4M Sep/2026
IQVIA Holdings USD 7.78B 1.04B Sep/2026
Kangmei Pharma CNY 5.1B 280.48M Jun/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Laboratorios Farma EUR 199.84M 121.75M Dec/2023
Laboratory Of America USD 2.82B 695M Sep/2026
Malin Corporation EUR 1000K 500K Dec/2024
Medical Developments International AUD 5.56M 2.26M Dec/2025
Mesa Laboratories USD 54.4M 6.1M Dec/2025
Mettler Toledo International USD 1.25B 49.81M Sep/2026
Myriad Genetics USD 130.7M 500K Jun/2026
Neuren Pharmaceuticals AUD 4.34M 3.58M Dec/2025
OraSure Technologies USD 25.12M 18.96M Jun/2026
Organigram Holdings CAD 107.28M 18.54M Jun/2026
Ovoca Bio EUR 1.3M 1.11M Dec/2025
Pacific Biosciences Of California USD 66.59M 2.21M Sep/2026
Pharma Mar EUR 125.39M 26.97M Sep/2026
Qiagen NV USD 581.45M 102.34M Jun/2026
Quest Diagnostics USD 1.83B 46M Sep/2026
Quidel USD 1.07B 73.7M Sep/2026
Repligen USD 125.69M 6.97M Sep/2026
Revvity USD 701.48M 574.88M Sep/2026
Sartorius EUR 1.55B 102.8M Sep/2026
Sino Biopharmaceutical CNY 24.85B 5.29B Jun/2025
Thermo Fisher Scientific USD 14.17B 899M Sep/2026
Tilray USD 259.32M 8.32M Sep/2025
Waters USD 2.4B 126M Jun/2026
Zealand Pharma A/S 404M 260.96M Mar/2026
Zz Pientze Pharmaceu CNY 2.74B 277.02M Sep/2026